BWV [NASD]
Blue Water Vaccines, Inc.
Index- P/E- EPS (ttm)-0.37 Insider Own27.50% Shs Outstand12.25M Perf Week-0.72%
Market Cap50.59M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.83M Perf Month12.84%
Income-4.00M PEG- EPS next Q- Inst Own10.90% Short Float11.43% Perf Quarter-91.67%
Sales- P/S- EPS this Y-87.30% Inst Trans- Short Ratio0.17 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.16 P/C26.63 EPS next 5Y- ROE- 52W Range3.26 - 90.90 Perf YTD-92.80%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-95.46% Beta-
Dividend %- Quick Ratio1.90 Sales past 5Y- Gross Margin- 52W Low26.69% ATR0.97
Employees5 Current Ratio1.90 Sales Q/Q- Oper. Margin- RSI (14)33.44 Volatility10.49% 30.39%
OptionableNo Debt/Eq0.00 EPS Q/Q-187.80% Profit Margin- Rel Volume0.14 Prev Close4.35
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.27M Price4.13
Recom- SMA20-11.22% SMA50-78.64% SMA200-85.90% Volume463,749 Change-5.06%
May-19-22 02:00PM  
May-13-22 05:01PM  
May-12-22 08:30AM  
May-11-22 01:00PM  
Apr-27-22 12:30PM  
12:30PM  
Apr-21-22 08:45AM  
Apr-20-22 09:25AM  
Apr-13-22 09:30AM  
Apr-11-22 09:56AM  
Apr-08-22 09:44AM  
Apr-01-22 05:04PM  
Mar-22-22 07:00AM  
Feb-23-22 04:51PM  
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.